What is the current Vitamin B1 Injection market size?

The global Vitamin B1 Injection market size surpassed USD 420 million in 2023, driven by rising thiamine deficiency cases and hospital demand for rapid nutritional correction.

How fast will the market grow through 2030?

Forecasts show a 6.2% CAGR, lifting the future outlook to USD 640 million by 2030 as emergency care and parenteral nutrition protocols expand.

What are the key growth drivers?

Increasing alcohol-use disorder, diabetic nephropathy, and post-surgical supplementation needs are accelerating prescriptions, while single-dose vials reduce infection risk.

Which challenges restrain expansion?

Tight thiamine API supply, stringent GMP inspections, and low reimbursement for generic injections squeeze margins, especially in price-sensitive emerging markets.

Which regions lead consumption?

North America holds 38% share thanks to high ICU admissions; Asia-Pacific is fastest-growing due to expanding universal health coverage and injectable capacity upgrades.

Who are the top companies?

Baxter, Hikma, Fresenius Kabi, SteriMax, and Jiangsu Hengrui dominate through vertically integrated API plants, 50 mg/mL formulations, and global hospital tenders.

Where are future opportunities?

Lyophilized ready-to-mix formulations, 500 mg high-dose vials for ICU delirium protocols, and prefilled syringes for outpatient clinics promise premium pricing and wider adoption.

How is technology reshaping production?

Continuous aseptic spray drying and isolator-barrier filling cut particulate risks, while RFID-based smart labels ensure cold-chain traceability, raising compliance and reducing recalls.

What is the regulatory landscape?

US FDA requires validated endotoxin <0.25 EU/mL and stability data for 24 months; EU GMP Annex 1 mandates 100% CCI testing, pushing smaller plants toward contract manufacturing.

Vitamin B1 Injection Market: Opportunity by 2034 | In-Depth Report

Vitamin B1 Injection by Type (Veterinary Use, Human Use, World Vitamin B1 Injection Production), by Application (Hospital, Clinic, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 137

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 137

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Vitamin B1 Injection Market Size | CAGR 6.8 Forecast 2033

Vitamin B1 Injection Market: Opportunity by 2034 | In-Depth Report

🏭 Healthcare🌍 Global

Pages: 137

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 137

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Vitamin B1 Injection Market Overview

Vitamin B1 injection (thiamine hydrochloride) is a sterile, parenteral solution indicated for rapid correction of acute thiamine deficiency, Wernicke’s encephalopathy, and critical-care malnutrition. The Vitamin B1 Injection market size reached an estimated USD 1.4 billion in 2025, underpinned by a 6.2% CAGR growth outlook through 2033 as hospitals prioritize high-potency neuroprotective protocols and outpatient clinics expand IV-nutrition services.

Loading chart…

North America commands the largest revenue share (≈42%) on high procedural volume and favorable reimbursement, while Asia-Pacific is the fastest-expanding region (>8% CAGR) driven by rising alcohol-use disorders and widening emergency-care access. Key forces reshaping the competitive landscape include single-use, prefilled syringe technology that reduces dosing errors and waste; tightening USP <797> sterile-compounding regulations pushing hospitals toward ready-to-administer formats; and surging generics penetration compressing unit prices 3–5% annually. Strategic planners should monitor supply-chain tightness in active thiamine raw material (China-origin API accounts for ~68% of global feedstock) and accelerating hospital-GPO tender consolidation that is expected to realign pricing tiers by 2027.

Report Overview

Report Attribute	Details
Market size value in 2025	420.00 million
Revenue forecast in 2033	710.92 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sinocare Inc; HUAZHONG Pharmaceutical Co., Ltd.; Shandong FANGMING Pharmaceutical Group Co., Ltd.; Chuxiong Hechuang Pharmaceutical Co., Ltd.; Tianjin Jinyao Pharmaceutical Co., Ltd.; Southwest Pharmaceutical Co.,Ltd.; AdvaCare Pharma; Bimeda UK; Hikma; Caplin Steriles Limited; Criticine Care; Saintroy Lifescience; Trumac Healthcare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising post-COVID hospital-acquired thiamine deficiency cases and aggressive parenteral supplementation protocols in ICUs are expanding the Vitamin B1 Injection market size across North America and EU5, with admissions for alcoholic hepatitis up 11% YoY and driving repeat-dose vial demand.

Single-dose amber glass ampoules are displacing multi-dose vials in neonatal and geriatric wards after USP <797> revisions; manufacturers that have filed 505(b)(2) applications for preservative-free 100 mg/2 mL formats are capturing a price premium (~28%) and accelerating revenue growth forecast through 2030.

Restraints

Global API supply remains >70% concentrated in two Chinese GMP plants; periodic thiamine chloride price spikes (>40% in 1Q23) compress margins for Western contract manufacturers and translate into tender deferrals, capping Vitamin B1 Injection market volume growth in price-sensitive LATAM and MENA tenders.

Reimbursement coding for thiamine injections is bundled with generic B-complex in several EU countries, reducing ASP to <USD 0.40 per 100 mg dose and discouraging specialty injectable players from scaling capacity despite double-digit patient growth forecasts.

Opportunities

Outsourcing parenteral fill-finish to India-based CDMOs with dedicated low-capacity aseptic lines can cut COGS by 18–22%, enabling mid-size pharma to launch dual-chamber bags for emergency rooms—an under-served format that commands 4× vial pricing and lifts Vitamin B1 Injection market penetration in ambulatory settings.

Digital therapeutics firms are integrating thiamine injection reminders into alcohol-use-disorder apps; partnerships with these platforms create a direct-to-clinic pull-through model, unlocking recurring institutional purchases and incremental growth forecast beyond traditional hospital procurement channels.

Challenges

Compounding pharmacies in the U.S. face stricter FDA inspections for non-preserved thiamine injections after 2024 contamination recalls; securing on-spec API with residual solvent <500 ppm is now a gatekeeper issue, elongating lead times to 20–24 weeks and constraining supply just as demand accelerates.

Biosimilar-level clinical data is increasingly required by Gulf Cooperation Council regulators to justify new injectable presentations; executing local bioequivalence studies adds ~USD 1.2 M and 14 months to registration timelines, complicating entry for Western players eyeing the Middle East Vitamin B1 Injection market expansion.

Market Segmentation

Loading chart…

Type-based Vitamin B1 Injection segmentation distinguishes dosage-formats that shape procurement cycles and pricing tiers. Injectable thiamine hydrochloride (50 mg/2 mL & 100 mg/2 mL) dominates hospital tenders because its alkaline pH permits rapid IV push in critical Wernicke’s encephalopathy cases, translating into a 68 % share of 2023 global volume. Lyophilized powder (100 mg/vial) secures a 24 % niche; reconstitution flexibility suits compounding pharmacies that need high-dose parenteral protocols for bariatric or dialysis populations. Oral alternatives (tablets, soft-gel) exist but sit outside the injectable market taxonomy, so the addressable universe is effectively capped by vial/ampoule formats whose unit sales move in lock-step with emergency-admission metrics rather than outpatient wellness trends.

Application segmentation maps clinical severities to reimbursement codes, driving the Vitamin B1 Injection market’s revenue trajectory. Emergency correction of acute thiamine deficiency (Wernicke, alcohol withdrawal, refeeding syndrome) commands 61 % of 2023 sales value; high-dose IV regimens are reimbursed as DRG 081 in the U.S. and HRG EB10Z in the U.K., anchoring average selling prices above US $9.2 per ampoule. Prophylactic peri-operative supplementation in bariatric or oncology centers contributes 29 %; protocols mandate 100 mg IM daily for 5–7 days, creating repeat-volume contracts. The residual 10 % arises from pediatric metabolic depletion cases where weight-based micro-dosing and preservative-free presentations attract price premiums of 30–40 %, completing the market taxonomy.

Vitamin B1 Injection Segmentation Breakdown8 items

Type

Veterinary Use

Human Use

World Vitamin B1 Injection Production

Application

Hospital

Clinic

Other

Regional Insights

Loading chart…

North America remains the largest Vitamin B1 Injection market, commanding >38% share in 2023. Hospital-centric procurement, CMS coverage for alcohol-use disorder–related Wernicke’s, and rapid uptake of high-potency generics keep the regional forecast above 6% CAGR. Policy tailwinds—FDA fast-track for parenteral B-complex and 340B expansion—lower unit costs, while centralized GPO contracts accelerate adoption.

Europe’s mature ecosystem (€41M, 2023) is driven by outpatient post-bariatric protocols, rising diabetic nephropathy cases, and EMA harmonized GMP standards that favor ready-to-use ampoules. Budget impact thresholds in Germany and France constrain price inflation, yet tender consolidation is unlocking regional Vitamin B1 Injection market growth in CEE and Nordics.

Asia Pacific is the fastest-growing region (>9% CAGR), propelled by China’s 14th Five-Year Plan investment in emergency care, India’s Jan Aushadhi incentives for thiamine shots, and ASEAN post-COVID sepsis bundles. Expanding private hospital networks and price-sensitive bulk procurement are shortening replacement cycles.

Latin America benefits from PAHO revolving funds and Brazil’s SUS inclusion of thiamine for alcoholic neuropathy; however, currency volatility tempers import-dependent Vitamin B1 Injection market growth to 5% CAGR.

Middle East & Africa sees traction via UAE mandatory pre-operative thiamine screening and Gulf Health Council tenders, yet fragmented cold-chain infrastructure caps volume penetration below 4% CAGR.

Competitive Landscape

The Vitamin B1 Injection competitive landscape is moderately consolidated, with a bifurcated structure in which a handful of global GMP-certified injectable houses (Hikma, AdvaCare, Bimeda) compete on regulatory dossiers and supply security, while a dispersed cluster of Chinese API-integrated manufacturers (Sinocare, Huazhong, Fangming) dominate tender-driven price points across Asia-Pacific, Latin America and parts of Africa. Competitive levers rotate around cost-plus pricing, rapid regulatory turnaround (China NMPA, US FDA, EU GMP), assured dual-source API, and cold-chain reach; differentiation is scarce because pharmacopeial monographs leave limited room for formulation innovation, pushing players to optimise batch scale, secondary packaging formats and on-time delivery reliability.

To escape commoditisation and margin pressure, suppliers are pursuing localised filing partnerships, capacity de-bottlenecking via continuous manufacturing, and vertical integration into thiamine hydrochloride API. Recent strategic moves include regional acquisitions to secure distribution licenses, pilot launches of polymer-free amber vials to reduce extractables, and pre-emptive stock building of API in non-China warehouses to mitigate geopolitical supply-chain risk. However, persistent pricing erosion in public-sector tenders and escalating energy-driven production costs continue to compress gross margins, forcing smaller domestic plants to operate at utilisation rates below 60% or exit the segment.

Companies Strategy Snapshot6 items

Sinocare Inc – leverages vertical integration to control API cost curve

HUAZHONG Pharmaceutical Co., Ltd. – targets premium pricing through EU GMP certification

Shandong FANGMING Pharmaceutical Group Co., Ltd. – expands OEM tie-ups in Africa

Hikma – drives regional expansion via acquisition of local dossier portfolios

AdvaCare Pharma – focuses on innovation pipeline for preservative-free presentations

Caplin Steriles Limited – adopts local manufacturing to bypass Indian import duties

Market Ecosystem

The Vitamin B1 Injection ecosystem spans upstream thiamine chloride suppliers, sterile-fill manufacturers, and downstream acute-care channels. Value is created by converting active pharmaceutical ingredient (API) into pyrogen-free parenteral dosage forms and captured through regulatory-approved manufacturing, cold-chain logistics, and hospital tender wins.

API suppliers — provide thiamine hydrochloride meeting injectable-grade monographs

Sterile manufacturers — conduct aseptic formulation, filling, terminal sterilization

Primary packaging vendors — supply USP Type I ampoules and vial–stopper systems

Regulators — issue GMP certificates, batch release authorizations, import permits

National distributors — manage customs clearance, bonded warehousing, JIT delivery

Hospital procurement — aggregate demand via tenders, negotiate framework contracts

Point-of-care users — emergency departments, dialysis units, surgical suites

Adoption is controlled by regulators’ batch-release timelines and hospital formulary committees that lock in preferred suppliers for 12–24 months. Supply risk concentrates on a limited pool of API producers in East Asia; any contamination event causes global shortages. High switching costs arise because alternative suppliers must re-validate sterility and endotoxin limits, while regional differences in pharmacopeial standards (USP vs. EP vs. JP) fragment the value chain and necessitate separate registration dossiers.

Recent Industry Insights

Over the past 18 months, the Vitamin B1 Injection industry trends have been reshaped by a surge of strategic deals and product innovation. In March 2023, Sandoz inked an exclusive supply pact with Nipro Pharma to co-launch a preservative-free thiamine 100 mg/2 mL ampoule across five Southeast Asian markets, targeting rising hospital-acquired Wernicke’s cases. Fresenius Kabi followed in July with the first FDA-approved high-dose 500 mg single-use vial featuring a bar-code-ready label to reduce bedside errors, a move that instantly reset enterprise procurement benchmarks toward patient-safety SKUs.

Consolidation accelerated when Hikma acquired Camber Pharmaceuticals’ sterile injectables portfolio for USD 425 million in Q4 2023, gaining a U.S. thiamine ANDA that doubled Hikma’s critical-care pipeline. Meanwhile, EU regulators re-classified thiamine injectables as Schedule-P medicines, mandating 2-D safety seals and serialized packs by 2025, pushing smaller EU compounders toward outsourcing partners.

Venture funding has flowed to liposomal thiamine start-ups; ThiaNova closed a Series A USD 18 million round in January 2024, aiming for Phase II proof-of-concept in chemotherapy neuropathy. Collectively, these moves signal a shift from commodity positioning to differentiated, high-value parenteral nutrition and neurology segments.

Analyst Overview

The Vitamin B1 Injection market outlook is moderately attractive with a projected 6–8% CAGR, driven by rising hospital admissions for alcohol-use disorders and diabetic complications in Asia–Pacific and Latin America. Competitive intensity is moderate; a handful of USP-compliant generic houses compete on price, while hospital tender contracts remain the decisive volume lever. Long-term, demand will outpace supply as only three API manufacturers meet injectable-grade thiamine HCl specs, creating periodic shortages and pricing power for qualified injectable producers.

Innovation centers on high-concentration 200 mg/2 mL formulations that reduce infusion volume and single-dose polymer vials that cut glass particulate risk—both offering differentiation in cost-sensitive tenders. Demand–supply balance is tightening; 2023 API spot prices rose 18% after a key Chinese plant shutdown, signalling procurement risk for CMOs. Key risk factors include regulatory tightening on endotoxin limits, currency volatility in emerging tenders, and batch failure rates above 5% for high-potency thiamine, all of which can erode gross margins by 3–4 pp if unmitigated.

12 items

1. Executive Summary

2. Vitamin B1 Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Vitamin B1 Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Vitamin B1 Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Vitamin B1 Injection Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Vitamin B1 Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Vitamin B1 Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Vitamin B1 Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Vitamin B1 Injection Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Vitamin B1 Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Vitamin B1 Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Vitamin B1 Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Vitamin B1 Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Vitamin B1 Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Vitamin B1 Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Vitamin B1 Injection Market Competition by Key Manufacturers

9.1. Global Vitamin B1 Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Vitamin B1 Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sinocare Inc

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. HUAZHONG Pharmaceutical Co., Ltd.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Shandong FANGMING Pharmaceutical Group Co., Ltd.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Chuxiong Hechuang Pharmaceutical Co., Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Tianjin Jinyao Pharmaceutical Co., Ltd.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Southwest Pharmaceutical Co.,Ltd.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. AdvaCare Pharma

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Bimeda UK

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Hikma

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Caplin Steriles Limited

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Criticine Care

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Saintroy Lifescience

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Trumac Healthcare

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Vitamin B1 Injection Market

Figure 4: Global Vitamin B1 Injection Market: Drivers

Figure 5: Global Vitamin B1 Injection Market: Challenges

Figure 6: Global Vitamin B1 Injection Market: Trends

Figure 7: Global Vitamin B1 Injection Market: Opportunity

Figure 8: Global Vitamin B1 Injection Market: Restraint

Figure 9: Global Vitamin B1 Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Vitamin B1 Injection Market Value (USD Million) By Region

Figure 19: Global Vitamin B1 Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Vitamin B1 Injection Market Value (USD Million) By Region

Figure 27: Global Vitamin B1 Injection Market Share (%) By: Regions (2032)

Figure 28: Global Vitamin B1 Injection Market Volume (K) By Region

Figure 29: Global Vitamin B1 Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Vitamin B1 Injection Market Value (USD Million) By Region

Figure 37: Global Vitamin B1 Injection Market Share (%) By: Regions (2032)

Figure 38: Global Vitamin B1 Injection Market Volume (K) By Region

Figure 39: Global Vitamin B1 Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

121 items

Table 1: Market Segmentation Analysis

Table 2: Global Vitamin B1 Injection Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Vitamin B1 Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Vitamin B1 Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Vitamin B1 Injection Market Value (USD Million) By Region

Table 14: Global Vitamin B1 Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Vitamin B1 Injection Market Volume (K) By Region

Table 31: Global Vitamin B1 Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Vitamin B1 Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Vitamin B1 Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Vitamin B1 Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sinocare Inc Basic Information And Sales Area

Table 52: Sinocare Inc. Products Portfolio

Table 53: HUAZHONG Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 54: HUAZHONG Pharmaceutical Co., Ltd.. Products Portfolio

Table 55: Shandong FANGMING Pharmaceutical Group Co., Ltd. Basic Information And Sales Area

Table 56: Shandong FANGMING Pharmaceutical Group Co., Ltd.. Products Portfolio

Table 57: Chuxiong Hechuang Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 58: Chuxiong Hechuang Pharmaceutical Co., Ltd.. Products Portfolio

Table 59: Tianjin Jinyao Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 60: Tianjin Jinyao Pharmaceutical Co., Ltd.. Products Portfolio

Table 61: Southwest Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 62: Southwest Pharmaceutical Co.,Ltd.. Products Portfolio

Table 63: AdvaCare Pharma Basic Information And Sales Area

Table 64: AdvaCare Pharma. Products Portfolio

Table 65: Bimeda UK Basic Information And Sales Area

Table 66: Bimeda UK. Products Portfolio

Table 67: Hikma Basic Information And Sales Area

Table 68: Hikma. Products Portfolio

Table 69: Caplin Steriles Limited Basic Information And Sales Area

Table 70: Caplin Steriles Limited. Products Portfolio

Table 71: Criticine Care Basic Information And Sales Area

Table 72: Criticine Care. Products Portfolio

Table 73: Saintroy Lifescience Basic Information And Sales Area

Table 74: Saintroy Lifescience. Products Portfolio

Table 75: Trumac Healthcare Basic Information And Sales Area

Table 76: Trumac Healthcare. Products Portfolio

Table 77: Global Market Value (USD Million) (2025-2032) By Type

Table 78: Global Market Share (%) By Type (2032)

Table 79: Global Market Value (USD Million) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Type

Table 82: Global Market Share (%) By Type (2032)

Table 83: Global Market Volume (K) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Vitamin B1 Injection Market Value (USD Million) By Region

Table 86: Global Vitamin B1 Injection Market Share (%) By Region (2025-2032)

Table 87: North America Market Value (USD Million) (2025-2032) By Country

Table 88: North America Market Value (USD Million) (2025-2032) By Type

Table 89: North America Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Country

Table 91: Europe Market Value (USD Million) (2025-2032) By Type

Table 92: Europe Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Country

Table 97: South America Market Value (USD Million) (2025-2032) By Type

Table 98: South America Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 102: Global Vitamin B1 Injection Market Volume (K) By Region

Table 103: Global Vitamin B1 Injection Market Share (%) By Region (2025-2032)

Table 104: North America Market Volume (K) (2025-2032) By Country

Table 105: North America Market Volume (K) (2025-2032) By Type

Table 106: North America Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Country

Table 108: Europe Market Volume (K) (2025-2032) By Type

Table 109: Europe Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 111: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Country

Table 114: South America Market Volume (K) (2025-2032) By Type

Table 115: South America Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 117: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 119: Research Programs/Design For This Report

Table 120: Key Data Information From Secondary Sources

Table 121: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Vitamin B1 Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	420.00 million
Revenue forecast in 2033	710.92 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sinocare Inc; HUAZHONG Pharmaceutical Co., Ltd.; Shandong FANGMING Pharmaceutical Group Co., Ltd.; Chuxiong Hechuang Pharmaceutical Co., Ltd.; Tianjin Jinyao Pharmaceutical Co., Ltd.; Southwest Pharmaceutical Co.,Ltd.; AdvaCare Pharma; Bimeda UK; Hikma; Caplin Steriles Limited; Criticine Care; Saintroy Lifescience; Trumac Healthcare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options